Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b/2 study of epcoritamab in relapsed or refractory chronic lymphocytic leukemia and Richter syndrome
MOH_2023-04-02_012496Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Mar 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Richter's syndrome (RS), sponsored by Genmab. Started Mar 2023; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)
Beyond the preview
Go deeper on MOH_2023-04-02_012496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-02_012496.